Publications by authors named "Rolando Paez Meireles"
Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha.
Front Cell Infect Microbiol
July 2021
Article Synopsis
- The study investigates the role of host genetics, specifically single nucleotide polymorphisms (SNPs) in interferon lambda genes, in the immune response and treatment outcomes for chronic hepatitis C (CHC) patients.
- Three specific SNPs (rs12979860-CC, rs8109886-CC, and rs8099917-TT) were identified as predictive markers for sustained virologic response (SVR), with rs12979860-CC showing the strongest association.
- The research also highlighted the relationship between these genetic markers and cytokine levels, indicating a modulating effect on inflammation and immunity that could influence not only hepatitis C treatment but also other infections.
Background: Several countries have used pegylation technology to improve the pharmacokinetic properties of essential drugs. Recently, a novel interferon alfa-2b protein conjugated to four-branched 12 kDa polyethylene glycol molecules was developed jointly between Cuba and Brazil. The aim of this study was to compare the pharmacokinetic properties of BIP48 (pegylated interferon alfa-2b from Bio-Manguinhos/Fiocruz, Brazil) to those of PEGASYS® (commercially available pegylated interferon alfa-2a from Roche Pharmaceutical).
View Article and Find Full Text PDFEndotoxins (also known as lipopolysaccharides (LPS)) are undesirable by-products of recombinant proteins, purified from Escherichia coli. LPS can be considered stable under a wide range of temperature and pH, making their removal one of the most difficult tasks in downstream processes during protein purification. The inherent toxicity of LPS makes their removal an important step for the application of these proteins in several biological assays and for a safe parenteral administration.
View Article and Find Full Text PDFPharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
BMC Pharmacol
November 2010
Background: Interferon (IFN) alpha conjugation to polyethylene glycol (PEG) results in a better pharmacokinetic profile and efficacy. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety properties of a new, locally developed, 40-kDa PEG-IFN alpha-2b preparation with a reference, commercially available PEG-IFN alpha-2a in healthy male volunteers.
Methods: A randomized, crossover, double-blind study with a 3-weeks washout period, was done.